Mounjaro Compounding Legal Status: What Patients and Prescribers Need to Know in 2025
A complete guide to the FDA approval status of tirzepatide (Mounjaro), the compounding pharmacy rules that apply, and what the current label permits and prohibits.
MOUNJARO: Regulatory History
8 source-based articles maintained by the HealthRX.com Editorial Team.
8articles
4topic areas covered
Jul 1, 2025latest review
MOUNJARO: Regulatory History library
Showing 8 of 8 clinical reviews.
Mounjaro EMA vs FDA: How Tirzepatide Regulation Differs Across Agencies
Mounjaro EMA product information: tirzepatide was authorised EU-wide on 15 September 2022, and the SmPC now covers type 2 diabetes and weight management.
Mounjaro FAERS Safety Signals: What FDA Post-Market Data Shows
A analysis of Mounjaro (tirzepatide) safety signals reported to FDA FAERS, including label warnings, real-world adverse event rates, and post-market surveillance findings.
Mounjaro Global Regulatory Status: FDA Approval, EMA Authorization, and Worldwide Label Updates
A complete guide to Mounjaro (tirzepatide) regulatory approvals worldwide, including FDA labeling, EMA authorization, post-market safety surveillance, and ongoing label expansions.
Mounjaro Label Updates 2020 to 2026: A Complete FDA Regulatory Timeline
Every FDA label change for Mounjaro (tirzepatide) from initial approval through 2026, including new indications, boxed warnings, safety communications, and post-market requirements.
Mounjaro Legal and Patent Challenges: FDA History, Litigation, and What Comes Next
A clinical review of Mounjaro (tirzepatide) legal battles, patent disputes, FDA approval timeline, label updates, and post-market safety surveillance.
Mounjaro Pipeline and Next-Gen: FDA Label, Safety Data, and What Comes After Tirzepatide
A comprehensive look at Mounjaro (tirzepatide) FDA approval history, current prescribing label, post-market safety surveillance, and the next-generation dual and triple agonist pipeline beyond tirzepatide.
Mounjaro Release Date: FDA Approval History & Timeline
Mounjaro was FDA approved May 13, 2022 for type 2 diabetes; Zepbound followed Nov 8, 2023 for obesity. See doses, mechanism, and boxed warning details.